에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

VEEVA SYSTEMS INC-CLASS A

Veeva Systems

Veeva Sys

Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.

Jakarta,-,August,15,2024:,Applovin,Corporation,Logo,Signboard.,Is,An

Large Cap

News

Movers

BWXT

HOLX

INTU

RDDT

ULTA

VEEV

지난주 최고의 성과를 보인 10개의 대형주는 다음과 같다. US스틸, 유니티 소프트웨어, 비바 시스템즈, BWX 테크놀로지스, 울타 뷰티, 레딧, 홀로직, 인튜이트, 헤이코, 앱러빈

US스틸, 앱러빈, 울타 뷰티 등 지난주 급등한 대형주 10종목 (5월 26일~30일)

Cathie Wood Offloads Meta Stock While Mark Zuckerberg Celebrates Llama AI Success

Equities

Markets

ETFs

ABSI

AMGN

ARKG

ARKK

ARKQ

ARKX

BEAM

ILMN

IRDM

PACB

RPTX

2025년 3월 21일 금요일, 캐시 우드가 이끄는 아크 인베스트는 몇 가지 주목할 만한 거래를 진행했으며, 여기에는 상당한 매수와 매도가 포함되었다. 아크 인베스트의 펀드는 이리듐 커뮤니케이션스(NASDAQ:IRDM), 빔 테라퓨틱스(NASDAQ:BEAM), 퍼시픽 바이오사이언스 오브 캘리포니아(NASDAQ:PACB), 및 앱시 코퍼레이션(NASDAQ:ABSI)를 매수한 반면, 일루미나(NASDAQ:ILMN), 리페어 테라퓨틱스(NASDAQ:RPTX), 암젠(NASDAQ:AMGN), 및 비바 시스템즈(NYSE:VEEV)의 주식을 매도했다.

아크 인베스트가 이리듐·빔·퍼시픽 바이오사이언스를 매수, 일루미나와 암젠을 매각

Earnings

Pre-Market Outlook

Trading Ideas

목요일(6일) 아침 미국 주식 선물이 하락하는 가운데, 투자자들의 관심을 끌 수 있는 주식들이 다음과 같다. 크로거, BJ&#39;s 홀세일 클럽, 비바 시스템즈, 메이시스 및 휴렛 팩커드 엔터프라이즈

목요일 주목해야 할 주식: 크로거, BJ&#39;s 홀세일 클럽, 비바 시스템즈, 메이시스 및 휴렛 팩커드 엔터프라이즈

Veeva Systems Inc

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected <a href="https://www.veeva.com/medtech/products/clinical/">Veeva Clinical Platform</a> applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from <a href="https://www.veeva.com/medtech/">Veeva MedTech</a>.

Veeva Systems Clinches Over 50 Medtech Clients As Industry Shifts From Outdated Tools To Smarter Clinical Platforms

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) has outperformed the market over the past 10 years by 15.66% on an annualized basis producing an average annual return of 26.71%. Currently, Veeva Systems has a market capitalization of $46.53 billion. 
Buying $1000 In VEEV: If an investor had bought $1000 of VEEV stock 10 years ago, it would be worth $10,519.39 today based on a price of $286.00 for VEEV at the time of writing.
<h3>Veeva Systems's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749487514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Veeva Systems 10 Years Ago Would Be Worth Today

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) and Sarah Cannon Research Institute (SCRI) today announced a strategic collaboration to drive speed and efficiency in oncology clinical trials across SCRI's more than 200 research site locations. SCRI is adopting <a href="https://www.veeva.com/products/veeva-clinical-platform/">Veeva Clinical Platform</a> to unify its contract research organization (CRO) and site management organization (SMO) on a single platform for seamless data flow across clinical teams and research sites.

Veeva Teams Up with Sarah Cannon to Speed Up Cancer Trials at 200+ Research Sites

<a href="https://www.veeva.com/">Veeva Systems</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) today announced Astellas has chosen <a href="https://www.veeva.com/products/crm-suite/crm/">Veeva Vault CRM</a>&nbsp;globally and <a href="https://www.veeva.com/cn/veeva-china-crm-suite-en/">Veeva China CRM</a> for China.
&nbsp;
"At Astellas, we discover and deliver transformative therapies for patients around the world," said Nick Eshkenazi, chief digital and transformation officer at Astellas. "Having a foundation for commercial agility and execution is crucial. Our collaboration with Veeva will provide us with technology solutions and data to enhance our agility as a company while we partner with an entity that shares our values and focus on patients."
"Astellas is a leader in improving the health of people around the world through their innovative science and healthcare solutions," said Matt Farrell, president, commercial strategy at Veeva. "With Vault CRM, we are excited to deepen our partnership to support Astellas in that mission."
Vault CRM addresses the industry's unique and evolving country-specific business needs and compliance requirements. It is part of the Vault CRM Suite that connects sales, marketing, and medical teams for seamless collaboration and more effective commercial execution.

Astellas Picks Veeva's Vault CRM to Boost Global Sales and Marketing Agility

Today, Accumulus Synergy ("Accumulus") announced a strategic partnership with Veeva Systems ("Veeva") focused on enabling connectivity to help the life sciences industry more effectively exchange regulated information with national regulatory authorities (NRAs) around the world. The partnership aims to empower customers with the tools needed to meet today's regulatory interoperability demands while maintaining the flexibility to adapt to the evolving regulatory technology landscape.
"Our partnership with Veeva is an important step forward in enabling our collective customers to maximize the benefit of the two technologies - Accumulus' single dossier in the cloud and Veeva's comprehensive Regulatory Information Management (RIM) platform," said Francisco Nogueira, CEO of Accumulus. "At Accumulus, we have seen tremendous cycle time improvements driven by our platform. Through this partnership, we're poised to significantly increase organizational efficiency for our customers by providing connectivity between Veeva RIM and the Accumulus platform."
The partnership is designed to bridge current requirements and emerging needs, supporting near-term connectivity while aligning with global efforts to modernize regulatory technology. It will enable life sciences organizations to seamlessly connect systems across borders and platforms without being locked into legacy approaches.
"Our customers are eager to find innovative solutions to drive efficiencies in NRA interactions and review cycles," said Marc Gabriel, Vice President, Regulatory at Veeva. "We look forward to working with Accumulus to build connections to advance the industry."
The Accumulus-Veeva partnership represents a shared vision for an ecosystem where collaboration drives progress and sponsors are empowered with meaningful solutions. Accumulus and Veeva are positioning the industry for sustainable innovation by bridging Veeva RIM and NRAs in the cloud.

Accumulus and Veeva Team Up to Speed Drug Approvals with Smarter Cloud Tools

Mizuho analyst Steven Valiquette maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $280 to $295.

Price Target

Analyst Ratings

Mizuho Maintains Outperform on Veeva Systems, Raises Price Target to $295

These ten large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>United States Steel Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares jumped 25.45%. Japan&#8217;s Nippon Steel is set to finalize its acquisition of the company at $55 per share, according to <a href="https://www.benzinga.com//node/45622810" target="_blank" rel="noreferrer noopener">sources familiar with the matter</a>.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) shares escalated 19.30% after Jefferies analyst Brent Thill upgraded the company from Hold to Buy and raised <a href="https://www.benzinga.com/quote/u/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast from $22 to $29</a>.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) shares rose 18.75% after multiple analysts raised their price forecasts on the stock. The company <a href="https://www.benzinga.com//node/45677373" target="_blank" rel="noreferrer noopener">recently raised its FY26 guidance</a>.</li>
<li>BWX Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) shares upped 16.71% as President Donald Trump signed a suite of executive orders to <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">revive the U.S. nuclear industry</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares increased 14.88% after the company reported better-than-expected first-quarter earnings and analysts <a href="https://www.benzinga.com//node/45695903" target="_blank" rel="noreferrer noopener">raised the price forecast on the stock</a>.</li>
<li>Reddit, Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) stock increased 14.27% after it was named among the <a href="https://www.benzinga.com//node/45679678" target="_blank" rel="noreferrer noopener">additions to the Russell 3000 index</a>.</li>
<li>Hologic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) stock grew 14.12% after private equity firms TPG and Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) recently bid to acquire the company, <a href="https://www.benzinga.com//node/45629538" target="_blank" rel="noreferrer noopener">valuing it at over $16 billion</a>.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) stock upped 13.12%, possibly amid overall market strength after President Trump delayed 50% EU tariffs to July.</li>
<li>Heico Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) shares were up 12.19% after the company reported <a href="https://www.benzinga.com//node/45630872" target="_blank" rel="noreferrer noopener">better-than-expected financial results</a>.</li>
<li>Applovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) stock gained 11.82% last week. It continued upward momentum following <a href="https://www.benzinga.com//node/45543602" target="_blank" rel="noreferrer noopener">strong Q1 earnings</a> and tariff <a href="https://www.benzinga.com//node/45655193" target="_blank" rel="noreferrer noopener">truce tailwinds</a>.</li>
</ol>
Photo via Shutterstock

United States Steel, Applovin And Ulta Beauty Are Among Top Large-Cap Gainers Last Week (May 26-May 30): Are The Others In Your Portfolio?

Citigroup analyst Tyler Radke maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $265 to $329.

Citigroup Maintains Buy on Veeva Systems, Raises Price Target to $329

Investors with a lot of money to spend have taken a bullish stance on Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VEEV, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 35 uncommon options trades for Veeva Systems.
This isn't normal.
The overall sentiment of these big-money traders is split between 54% bullish and 25%, bearish.
Out of all of the special options we uncovered, 13 are puts, for a total amount of $438,641, and 22 are calls, for a total amount of $1,446,806.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $370.0 for Veeva Systems over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Veeva Systems stands at 360.07, with a total volume reaching 12,543.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Veeva Systems, situated within the strike price corridor from $200.0 to $370.0, throughout the last 30 days.
<h3>Veeva Systems Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748548852_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$16.0</td>
<td>$14.8</td>
<td>$16.0</td>
<td>$320.00</td>
<td>$195.2K</td>
<td align="right">3</td>
<td align="right">561</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$37.0</td>
<td>$35.0</td>
<td>$36.0</td>
<td>$280.00</td>
<td>$162.0K</td>
<td align="right">111</td>
<td align="right">49</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$13.8</td>
<td>$12.6</td>
<td>$13.8</td>
<td>$320.00</td>
<td>$121.4K</td>
<td align="right">3</td>
<td align="right">964</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$45.0</td>
<td>$43.3</td>
<td>$45.0</td>
<td>$240.00</td>
<td>$90.0K</td>
<td align="right">814</td>
<td align="right">140</td>
</tr>
<tr>
<td>VEEV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$44.5</td>
<td>$43.1</td>
<td>$44.5</td>
<td>$240.00</td>
<td>$89.0K</td>
<td align="right">814</td>
<td align="right">120</td>
</tr>
</tbody>
</table>

<h3>About Veeva Systems</h3>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>Where Is Veeva Systems Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,436,994, with VEEV's price up by 18.8%, positioned at $278.57.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Expert Opinions on Veeva Systems</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $272.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Barclays persists with their Overweight rating on Veeva Systems, maintaining a target price of $300. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Veeva Systems, which currently sits at a price target of $325. 
&#x2A; An analyst from Morgan Stanley persists with their Underweight rating on Veeva Systems, maintaining a target price of $210. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Veeva Systems, targeting a price of $230. 
&#x2A; An analyst from Stifel has decided to maintain their Buy rating on Veeva Systems, which currently sits at a price target of $295. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Veeva Systems options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

Smart Money Is Betting Big In VEEV Options

Wells Fargo analyst Stan Berenshteyn maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $285 to $300.

Wells Fargo Maintains Overweight on Veeva Systems, Raises Price Target to $300

WIIM

Veeva Systems shares are trading higher after multiple analysts raised their price targets on the stock. The company recently raised its FY26 guidance.

Wall Street hovered slightly higher by midday Thursday, giving up a chunk of strong overnight gains in futures markets that were triggered by a federal court ruling suspending a large portion <a href="https://www.benzinga.com/government/regulations/25/05/45672421/tariffs-blocked-by-court-but-goldman-sachs-says-trump-could-reimpose-them-within-days">of President Donald Trump&#8217;s tariffs.</a>
Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) led the market after reporting a better-than-feared quarter. The artificial intelligence leader showed resilience in the face of export restrictions. Shares rose 4.3%, ranking as the second-best performer on the S&amp;P 500 and climbing to their highest level in more than three months.
By midday: 
<ul class="wp-block-list">
<li>The S&amp;P 500 was up 0.3% at 5,900.</li>
<li>The Nasdaq 100 gained 0.5%.</li>
<li>The Dow Jones Industrial Average traded flat.</li>
</ul>
<h3 class="wp-block-heading">Fresh Economic Data Adds To Mixed Tone</h3>
First-quarter U.S. gross domestic product shrank 0.2%, slightly improving from the initial 0.3% estimate. Still, it marked a sharp slowdown compared to the 2.4% growth in the last quarter of 2024, reflecting slower consumer spending and higher imports ahead of the tariffs impact.
More concerning was the labor market. Initial jobless claims for the week ending May 24 jumped to 240,000, exceeding expectations and reaching their highest level in nearly four months. Continuing claims also rose to levels last seen in November 2021, indicating potential softening in employment trends.
The U.S. dollar pulled back, nearly wiping out gains from the prior two sessions as traders reassessed the outlook for interest rates. Meanwhile, Treasury yields dropped, with the 30-year note falling to 4.92% and the 10-year yield easing to 4.42%.
Federal Reserve Chair Jerome Powell met with Trump at the White House, the Fed confirmed.
The meeting focused on recent economic developments, including inflation, employment and growth. Powell reiterated that the Fed&#8217;s policy path would remain dependent on incoming data but refrained from commenting on future rate decisions.
Gold climbed 1.1% to $3,320 per ounce, buoyed by lower yields and dollar weakness. Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell below $107,000, giving up recent gains as risk appetite moderated in crypto markets.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,414.87</td>
<td>0.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,906.48</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,069.76</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,091.08</td>
<td>0.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) inched 0.3% up to $589.37.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.1% to $420.98.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.4% to $520.87.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) flattened at $205.62.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.4%; the&nbsp;Communication Services&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) lagged, down 1.1%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Shares of E.l.f. Beauty, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) surged 26% Thursday afternoon, following the company&#8217;s announcement of its acquisition of lifestyle cosmetics brand Rhode.</li>
<li>Sentinel One Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) tumbled 11% after BofA Securities downgraded&nbsp;the stock from &#8216;Buy&#8217; to &#8216;Neutral&#8217; citing &#8220;weak trends and lackluster guidance&#8221; while lowering its price target from $24 to $21. </li>
</ul>
Stocks reacting to earnings included: 
<ul class="wp-block-list">
<li>Salesforce, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) down 5.42%</li>
<li>Synopsys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>) up 0.20%</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) up 18.45%</li>
<li>Agilent Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) up 3.17%</li>
<li>HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) down 8.23%</li>
<li>Hormel Foods Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRL#NYSE">HRL</a>) down 0.35%</li>
<li>Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) down 3.22%</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) down 7.90%</li>
<li>Nordson Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDSN#NASDAQ">NDSN</a>) up 5.65%</li>
<li>Hamilton Lane Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NASDAQ">HLNE</a>) down 11.21%</li>
<li>Roivant Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) up 5.50%</li>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) down 6.24%</li>
<li>Foot Locker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) up 0.10%</li>
</ul>
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">Nvidia Stock Has &#8216;Significant Upside&#8217; As AI &#8216;Godfather&#8217; Jensen Huang Delivers Another &#8216;Robust Quarter&#8217; </a></li>
</ul>
Image: Shutterstock

Government

Macro Economic Events

Regulations

Bonds

Broad U.S. Equity ETFs

Treasuries

Economics

Federal Reserve

$BTC

BBWI

BURL

SPDR Dow Jones Industrial Average ETF Trust

HLNE

NDSN

NVDA

ROIV

SNPS

Select Sector SPDR-Consumer Discretionary

Stocks Edge Higher After Court Stifles Trump Tariffs, Nvidia Rallies To 3-Month Highs, Bitcoin Dips Below $107K: What's Driving Markets Thursday?

Stifel analyst David Grossman maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Buy and raises the price target from $272 to $295.

Stifel Maintains Buy on Veeva Systems, Raises Price Target to $295

UBS analyst Karl Keirstead maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Neutral and raises the price target from $250 to $285.

UBS Maintains Neutral on Veeva Systems, Raises Price Target to $285

Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) posted better-than-expected earnings for the first quarter and raised the <a href="https://www.benzinga.com/quote/VEEV/earnings">outlook on Wednesday.</a>
The company reported adjusted earnings per share of $1.97, beating the analyst consensus estimate of $1.77. Quarterly sales of $759 million (+17% year over year) outpaced the Street view of $731.91 million.
"We crossed our 2025 revenue run rate goal this quarter and are progressing well toward our 2030 goal to double that and the positive impact we can have for our customers and the industry," said CFO Brian Van Wagener.
For the fiscal second quarter ending July 31, Veeva expects total revenue between $766 million and $769 million (Street View: $765.34 million), non-GAAP operating income between $335 million and $337 million and adjusted diluted EPS between $1.89 and $1.90 (Street view: $1.88).
For the full fiscal year ending January 31, 2026, the company projects total revenue between $3.09 billion and $3.10 billion versus the Street view of $3.09 billion (prior view: $3.040 billion to $3.055 billion), non-GAAP operating income of approximately $1.36 billion, and adjusted diluted EPS of around $7.63 versus the Street view of $7.56 (Prior view: $7.32).
Veeva shares jumped 18.1% to trade at $277.04 on Thursday.
These analysts made changes to their price targets on Veeva following earnings announcement.
<ul class="wp-block-list">
<li>Barclays analyst Saket Kalia maintained Veeva Systems with an Overweight rating and raised the price target from $285 to $300.</li>
<li>Morgan Stanley analyst Craig Hettenbach maintained the stock with an Underweight rating and raised the price target from $201 to $210.</li>
<li>Piper Sandler analyst Brent Bracelin maintained Veeva with an Overweight rating and raised the price target from $255 to $325.</li>
<li>Raymond James analyst Brian Peterson maintained the stock with an Outperform rating and raised the price target from $285 to $310.</li>
</ul>
Considering buying VEEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/VEEV/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-1024x586.png" alt="" class="wp-image-931996" style="width:673px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29131949/image-394.png 1122w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45667868/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Veeva Systems Analysts Boost Their Forecasts After Better-Than-Expected Earnings

Truist Securities analyst Joe Meares maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Hold and raises the price target from $217 to $230.

Truist Securities Maintains Hold on Veeva Systems, Raises Price Target to $230

Raymond James analyst Brian Peterson maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $285 to $310.

Raymond James Maintains Outperform on Veeva Systems, Raises Price Target to $310

Piper Sandler analyst Brent Bracelin maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $255 to $325.

Piper Sandler Maintains Overweight on Veeva Systems, Raises Price Target to $325

Morgan Stanley analyst Craig Hettenbach maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Underweight and raises the price target from $201 to $210.

Morgan Stanley Maintains Underweight on Veeva Systems, Raises Price Target to $210

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $285 to $300.

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $300

Press Releases

Life Sciences Leaders Advance Unified Engagement at Veeva Commercial Summit

Veeva to Release Fiscal 2026 First Quarter Results on May 28, 2025

More Than 75 Emerging Biotechs Use Veeva Basics Across Clinical, Regulatory, and Quality

Veeva Announces Fiscal 2026 First Quarter Results

Veeva Pulse Report Finds Content-Driven Engagement Lags Despite Proven Boost to Treatment Adoption

Veeva to Present at Upcoming Investor Conferences

Veeva and Sarah Cannon Research Institute Form Strategic Collaboration to Advance Oncology Clinical Trials

Astellas Chooses Veeva Vault CRM as Global Standard

New Study Finds 88% of Medtechs Prioritizing Postmarket Quality Modernization Within Next 3 Years

Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Firefly Neuroscience, Inc. - Common Stock

Firefly Neuroscience

American Well Corporation Class A Common Stock

American Well

CareCloud

Certara

Claritev Corporation Class A Common Stock

Claritev

Definitive Healthcare Corp. - Class A Common Stock

Definitive Healthcare

Doximity

DarioHealth

Evolent Health

Forian

GoodRx Holdings, Inc. - Class A Common Stock

GoodRx Holdings

Health Catalyst

HealthStream

icad

LifeMD

OptimizeRx

Phreesia

Pheton Holdings Ltd - Class A Ordinary Shares

Pheton Holdings

Schrodinger

Simulations Plus

Sophia Genetics

Streamline Health Solutions, Inc. - Common Stock

Streamline Health Solns

TruBridge

Teladoc Health

Waystar Holding

Mizuho

Citigroup

Wells Fargo

Piper Sandler

Stifel

지난주 최고의 성과를 보인 10개의 대형주는 다음과 같다.
<ol class="wp-block-list">
<li>US스틸(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) 주가는 25.45% 급등했다. 일본제철이 US스틸알 주당 55달러에 인수하기 위한 최종 절차를 밟고 있다고 <a href="https://www.benzinga.com//node/45622810" target="_blank" rel="noreferrer noopener">관계자들에 따르면</a> 전해졌다.</li>
<li>유니티 소프트웨어(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) 주가는 제프리스 애널리스트인 브렌트 틸이 회사 투자의견을 보유에서 매수로 상향 조정하고 <a href="https://www.benzinga.com/quote/u/analyst-ratings" target="_blank" rel="noreferrer noopener">목표주가를 22달러에서 29달러로 상향</a>한 이후 19.30% 상승했다.</li>
<li>비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) 주가는 여러 애널리스트들이 회사 목표주가를 상향 조정한 후 18.75% 상승했다. 비바 시스템즈는 <a href="https://www.benzinga.com//node/45677373" target="_blank" rel="noreferrer noopener">FY26 가이던스를 최근에 상향 조정</a>했다.</li>
<li>BWX 테크놀로지스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWXT#NYSE">BWXT</a>) 주가는 도널드 트럼프 대통령이 <a href="https://www.benzinga.com//node/45654523" target="_blank" rel="noreferrer noopener">미국 원자력 산업을 부활시키기 위한 여러 행정명령에 서명</a>한 후 16.71% 상승했다.</li>
<li>울타 뷰티(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) 주가는 이 회사가 예상보다 좋은 1분기 실적을 보고한 후 14.88% 상승했으며, 애널리스트들이 <a href="https://www.benzinga.com//node/45695903" target="_blank" rel="noreferrer noopener">목표주가를 올렸다</a>.</li>
<li>레딧(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) 주가는 러셀 3000 지수에 <a href="https://www.benzinga.com//node/45679678" target="_blank" rel="noreferrer noopener">편입되는 것으로 발표되면서</a> 14.27% 상승했다.</li>
<li>홀로직(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) 주가는 사모펀드 TPG와 블랙스톤 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>)가 최근 이 회사를 인수하기 위해 입찰한 후 <a href="https://www.benzinga.com//node/45629538" target="_blank" rel="noreferrer noopener">회사의 가치를 160억 달러 이상으로 평가했다</a>는 소식에 14.12% 상승했다.</li>
<li>인튜이트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) 주가는 트럼프 대통령이 EU 50% 관세를 7월로 연기한 후 전체 시장 강세 속에서 13.12% 상승했다.</li>
<li>헤이코 코퍼레이션(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) 주가는 회사가 <a href="https://www.benzinga.com//node/45630872" target="_blank" rel="noreferrer noopener">예상보다 좋은 재무 실적을 보고</a>한 후 12.19% 상승했다.</li>
<li>앱러빈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) 주가는 지난주 11.82% 상승했다. 회사는 <a href="https://www.benzinga.com//node/45543602" target="_blank" rel="noreferrer noopener">강력한 1분기 실적</a>과 관세 <a href="https://www.benzinga.com//node/45655193" target="_blank" rel="noreferrer noopener">휴전의 여파</a>로 상승세를 이어갔다.</li>
</ol>
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

2025년 3월 21일 금요일, 캐시 우드가 이끄는 아크 인베스트는 몇 가지 주목할 만한 거래를 진행했으며, 여기에는 상당한 매수와 매도가 포함되었다.
아크 인베스트의 펀드는 이리듐 커뮤니케이션스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>), 빔 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>), 퍼시픽 바이오사이언스 오브 캘리포니아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>), 및 앱시 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>)를 매수한 반면, 일루미나(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), 리페어 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPTX#NASDAQ">RPTX</a>), 암젠(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), 및 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>)의 주식을 매도했다.
IRDM 거래: 아크 인베스트의 ARK Innovation ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>), ARK Autonomous Technology &amp; Robotics ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>), 및 ARK Space Exploration &amp; Innovation ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) 펀드가 이리듐 커뮤니케이션스의 주식 68,355주를 총 매수했다.
마지막 종가 27.65달러를 기준으로 매수한 주식들의 총 가치는 약 189만 달러이다.
BEAM 거래: 아크 인베스트의 ARKK 및 Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) 펀드가 총 28,717주의 빔 테라퓨틱스주식을 매수했다.
마지막 종가 23.3달러을 기준으로 매수한 주식들의 총 가치는 약 669,106달러이다.
PACB 거래: 아크 인베스트의 ARKK 펀드가 퍼시픽 바이오사이언스 오브 캘리포니아의 주식 243,300주를 매수했다.
마지막 종가 1.3달러를 기준으로 매수한 주식들의 총 가치는 약 316,290달러이다.
기타 주요 거래:
<ul>
<li>일루미나: 아크 인베스트는 ARKK와 ARKG를 통해 총 42,616주의 주식을 매도했다.</li>
<li>앱시 코퍼레이션: 아크 인베스트는 ARKG를 통해 71,392주의 주식을 매수했습니다.</li>
<li>리페어 테라퓨틱스: 아크 인베스트는 ARKG를 통해 54,786주의 주식을 매도했다.</li>
<li>암젠: 아크 인베스트는 ARKG를 통해 990주의 주식을 매도했다.</li>
<li>비바 시스템즈: 아크 인베스트는 ARKG를 통해 1,322주의 주식을 매도했다.</li>
</ul>
다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/03/44434973/tesla-record-highest-trade-ins-amid-backlash-against-ceo-elon-musk-surge-in-vandalism">테슬라, CEO 일론 머스크에 대한 반발과 기물 파손 급증 속 역대 최고 거래량 기록</a></li>
</ul>
면책 조항: 이 내용은 AI 도구의 도움을 받아 부분적으로 작성되었으며, Benzinga 편집자에 의해 검토되고 게시되었습니다.
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일(6일) 아침 미국 주식 선물이 하락하는 가운데, 투자자들의 관심을 끌 수 있는 주식들이 다음과 같다.
<ul>
<li>BJ's 홀세일 클럽 홀딩스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>): 분기 주당순이익 88센트, 매출 53억 2천만 달러로 예상하고 있다. 수요일 애프터마켓에서 주식은 0.1% 하락하여 100.06달러에 거래되었다.</li>
<li>크로거(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>): 목요일 개장 전 실적을 발표할 예정이며, 분기 주당순이익 1.11달러, 매출 345억 1천만 달러로 예상한다. 수요일 애프터마켓에서 주식은 0.27% 하락한 62.36달러에 거래되었다.</li>
<li>비바 시스템즈 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>): 4분기 매출이 7억 2,090만 달러로 전년 대비 14% 증가했다고 보고했다. 이라한 매출은 애널리스트들이 예상한 6억 9,911만 달러를 초과한 수치다. 회사는 전체 회계연도 매출 가이던스를 30억 4천만 달러에서 30억 5천 5백만 달러 사이로 제시했으며, 애널리스트 예상치 30억 5천 5백만 달러와 일치한다. 회사는 전체 연도 주당순이익(EPS)을 7.32달러로 전망했고, 이는 애널리스트 예상치 6.91달러를 초과하는 수치다. 주식은 수요일 애프터마켓에서 7.16% 상승한 235.69달러에 거래되었다.</li>
</ul>
자세한 내용은 <a href="https://www.benzinga.com/premarket/" target="_blank" rel="noopener">프리마켓 보도</a>를 확인하세요.
<ul>
<li>메이시스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>): 목요일 개장 전 실적을 발표할 예정이며, 분기 주당순이익 1.53달러, 매출 78억 7천만 달러로 예상된다. 주식은 수요일 애프터마켓에서 0.5% 상승한 13.37달러에 거래되었다.</li>
<li>휴렛 팩커드 엔터프라이즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>): 목요일 폐장 후 실적을 발표할 예정이며, 분기 주당순이익 49센트 매출 78억 2천만 달러로 예상된다. 주식은 수요일 애프터마켓에서 0.3% 상승한 18.89달러에 거래되었다.</li>
</ul>
사진 출처: Shutterstock
다른 트레이더들보다 30분 일찍 시장 움직임에 대한 독점 뉴스를 받아보세요.
Benzinga Pro의 독점 뉴스를 통해 수백만 명의 다른 트레이더보다 더 빠르게 유용한 투자 뉴스를 확인할 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

목요일 주목해야 할 주식: 크로거, BJ's 홀세일 클럽, 비바 시스템즈, 메이시스 및 휴렛 팩커드 엔터프라이즈

원격 근무와 사무실 근무 의무에 대한 논쟁이 계속되는 가운데, 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>), 클라우드 기반 소프트웨어 회사가 주목받고 있습. 이는 원격 근무(WFH) 정책을 수용하는 것이 어떻게 <a href="https://www.benzinga.com/top-stories/24/09/40887347/amazon-to-cut-management-layers-end-work-from-home" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">성공적인 전략이 될 수 있는지</a>를 보여주는 대표적인 사례이다.
비바는 2024년 원격 채용 공고가 가장 많았으며 연간 급여가 55,000~300,000달러에 달하는 역할을 제공했다고 포춘(Fortune)이 <a href="https://fortune.com/2025/01/24/veeva-most-remote-job-postings-wfh-rto/" target="_blank" rel="noreferrer noopener">보도</a>하며 플렉스잡스(FlexJobs)를 인용했다. 이는 유연성을 추구하는 구직자들에게 회사를 매우 매력적으로 만들었다. 특히 고용 시장이 보수가 좋은 원격 기회에 여전히 굶주려 있기 때문에 더욱 그렇다.
원격 근무가 주식 수익률을 높일까?
비바의 원격 근무 성공 사례는 직원들에게만 이로운 것이 아니라, 포춘이 덧붙인 바와 같이 건전한 비즈니스 전략이기도 하다. 연구에 따르면, 원격 근무 옵션을 제공하는 회사들이 더 나은 주식 수익률을 기록하고 더 높은 질의 인재를 유치하는 경향이 있다.
멜버른 대학교의 금융학 조교수 가브리엘레 라탄지오(Gabriele Lattanzio)가 발표한 <a href="https://editorialexpress.com/cgi-bin/conference/download.cgi?db_name=SIEP2021&amp;paper_id=58" target="_blank" rel="noreferrer noopener">논문</a>에 따르면, 원격 근무를 제공하는 회사들이 시장을 초과하여 7.44% 더 높은 수익률을 기록했다.
이러한 회사들은 또한 더 좋은 수익 결과와 긍정적인 주가 반응을 보였다.
<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">벤징가 프로</a>에 따르면, VEEV 주식은 지난 1년 동안 7% 이상 상승했다. 투자자들은 First Trust Nasdaq Lux Digital Health Solutions ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKG#NASDAQ">EKG</a>)를 통해 이 주식에 투자할 수 있다.
비바의 원격 근무 유연성 vs JP모건의 사무실 의무:
2007년에 설립된 비바의 원격 중심 접근 방식은 회사의 문화에 처음부터 뿌리내려 있었다. 창립자들이 회사 초기 몇 년 동안 서로 다른 도시에서 운영되었기 때문이다.
하지만 비바의 전략은 직원의 반발에 직면한 JP모건 체이스 &amp; 컴퍼니(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)와는 뚜렷한 대조를 이룬다. JP모건은 최근 직원들에게 주 5일 사무실 복귀를 요구하는 의무를 부과하여 큰 반발을 사고 있다. 이는 포춘이 이달 초 보도한 바 있다.
JPM 주식은 지난 1년 동안 53% 이상 상승했다. 투자자들은 iShares U.S. Financial Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYG#NYSE">IYG</a>)를 통해 이 주식에 투자할 수 있다.
실제로 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), 마이크로소프트(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) 및 골드만삭스 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)과 같은 주요 기업들은 직원들의 광범위한 저항에도 불구하고 사무실 복귀(RTO) 정책을 추진하고 있다.
이 회사의 직원들은 불만을 표시하며, 일부는 청원이나 퇴사를 통해 항의하기도 했다고 포춘이 덧붙였다.
일의 미래: 원격 근무가 자리잡을 수 있을까?
연구에 따르면, 주 2일 재택 근무를 하는 직원들은 매일 사무실에 출근하는 직원들과 동일한 생산성을 보인다고 한다. 이는 포브스가 Resume.org의 설문조사를 인용하여 보도한 내용이다. 그럼에도 불구하고, 28%의 비즈니스 리더가 2025년까지 100% 대면 근무를 강제할 계획인 반면, 2%만이 주 1일 미만의 사무실 근무를 허용할 것이다.
일의 미래가 진화함에 따라, 비바의 원격 근무를 통한 직원 행복과 생산성에 대한 집중은 점점 더 경쟁이 치열해지는 노동 시장에서 회사를 차별화하고 있다.

다음 읽기:
<a href="https://www.benzinga.com/markets/equities/25/01/43216784/doug-ford-takes-on-trump-ontario-premier-threatens-swift-retaliation-in-trade-war">더그 포드가 트럼프에게 도전: 온타리오 주지사가 무역 전쟁에서 신속한 보복을 위협합니다</a>
이미지 출처: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

General

AMZN

GOOG

GOOGL

MSFT

원격 근무 vs 오피스 복귀: 비바의 유연성이 JP모건의 사무실 지침을 능가할 수 있을까?

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 어펌 홀딩스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>)의 주가는 강력한 4분기 실적과 낙관적인 <a href="https://www.benzinga.com//node/40613433" target="_blank" rel="noreferrer noopener">1분기 가이던스</a>에 따라 36.04% 상승했다. 몇몇 분석가는 <a href="https://www.benzinga.com//node/40630056" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
2. 뉴타닉스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>)는 회사가 4분기 재무 결과를 보고하고 1분기 및 2025 회계연도 <a href="https://www.benzinga.com//node/40614905" target="_blank" rel="noreferrer noopener">매출 가이던스를 예상치</a>보다 높게 발표한 후 18.80% 상승했다. 많은 분석가들이 <a href="https://www.benzinga.com//node/40626089" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
3. 몽고DB(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>)는 예상보다 나은 2분기 재무 결과와 강력한 지침을 발표하여 지난주 주가가 16.32% 상승했다. 몇몇 분석가들이 <a href="https://www.benzinga.com/quote/MDB/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 전망을 상향 조정</a>했다.
4. 베스트 바이(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>)가 2분기 실적을 보고하고 <a href="https://www.benzinga.com//node/40624075" target="_blank" rel="noreferrer noopener">2025 회계연도 실적 가이던스를 상향 조정</a>한 후 주가는 13.54% 상승했다. 몇몇 분석가들은 <a href="https://www.benzinga.com//node/40651188" target="_blank" rel="noreferrer noopener" data-google-interstitial="false">주식에 대한 전망을 높였다</a>.
5. GE 베르노바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>)의 주식은 투자 은행 윌리엄 블레어(William Blair)가 주식을 <a href="https://www.benzinga.com/quote/GEV/analyst-ratings" target="_blank" rel="noreferrer noopener">아웃퍼폼 등급으로 커버리지를 개시</a>한 후 11.62% 상승했다.
6. 트립닷컴 그룹(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>)의 주식은 회사가 <a href="https://www.benzinga.com//node/40564652" target="_blank" rel="noreferrer noopener">분기 실적을 발표</a>한 후 11.42% 상승했다.
7. 쿠퍼 컴퍼니스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>)의 주식은 3분기 실적을 발표하고 예상치를 상회하는 <a href="https://www.benzinga.com//node/40611992" target="_blank" rel="noreferrer noopener">4분기 및 2025 회계연도 가이던스를 발표</a>한 후 11.30% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/COO/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
8. 인슐렛 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>)의 주식은 최근 자사의 패치형 웨어러블 인슐린 펌프인 옴니팟(Omnipod)이 <a href="https://www.benzinga.com//node/40562757" target="_blank" rel="noreferrer noopener">미국에서 제2형 당뇨병 환자</a>에게 사용하도록 지정되었다고 발표한 후 주가는 9.94% 상승했다.
9. 비바 시스템즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>)의 주식은 회사가 재무 실적을 발표하고 3분기 및 2025 회계연도 조정 <a href="https://www.benzinga.com//node/40611557" target="_blank" rel="noreferrer noopener">EPS 가이던스를 예상치 이상으로 발표</a>한 후 8.44% 상승했다. 여러 애널리스트들이 <a href="https://www.benzinga.com/quote/veev/analyst-ratings" target="_blank" rel="noreferrer noopener">주가 목표를 상향 조정</a>했다.
10. 아스펜 테크놀로지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>)의 주식은 8.12% 상승했다.
다음 읽기:
<a href="https://kr.benzinga.com/news/usa/stocks/%eb%8b%ac%eb%9f%ac-%ec%a0%9c%eb%84%88%eb%9f%b4-%eb%b0%8f-%ed%85%8c%eb%ac%b4%ec%9d%98-%eb%aa%a8%ed%9a%8c%ec%82%ac-pdd%eb%8a%94-%ec%a7%80%eb%82%9c%ec%a3%bc-%ec%b5%9c%ec%95%85%ec%9d%98-%ec%84%b1%ea%b3%bc/" target="_blank" rel="noopener">달러 제너럴 및 PDD는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (8월 25일-8월 31일)</a>
Affirm 제공
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Veeva Systems

뉴스

에 대한 최신 뉴스 Veeva Systems (NYSE:VEEV) 주식

일요일, 6월 01, 2025

토요일, 3월 22, 2025

목요일, 3월 06, 2025

월요일, 1월 27, 2025

화요일, 9월 03, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌